Astrazeneca Pharma IND LT
NSE: ASTRAZEN · Pharmaceuticals · sector
₹6,051.50NSE close 2026-10-26
Key numbers
Market cap₹15,129 cr
Price₹6,051.50
52w high / low₹9,850 / ₹5,640
P/E89.2xSector median 27.9x
P/B17.3xSector median 2.9x
Book value₹349.1
Dividend yield0.52%Sector median 0.48%
ROE20.6%Sector median 11.7%
ROCE26.8%Sector median 12.3%
OPM9.2%Sector median 14.0%
Debt / equity0.00xSector median 0.16x
EV/EBITDA65.3xSector median 18.6x
Interest cover40.9x
Current ratio1.76x
Sales growth 3y+31.4%Sector median +9.6%
Profit growth 3y+23.6%Sector median +13.3%
PEG3.78x
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹449 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 40.9x in the last 12 months.
- No promoter shares are pledged.
- Operating cash flow was below net profit in 4 of the last 5 years (FY26, FY25, FY24, FY23).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 16% of net profit in the last 12 months.
- Dividend paid in 5 of the last 5 financial years.
- Price ₹6,051.50 on 2026-10-26: -38.6% from the 52-week high, +7.3% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹10,069.00 · low ₹5,837.00
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 408 | 440 | 480 | 526 | 559 | 612 | 579 | 683 |
| EBITDA | 53 | 43 | 81 | 81 | 70 | 46 | 60 | 49 |
| OPM % | 12.9% | 9.9% | 16.8% | 15.3% | 12.5% | 7.6% | 10.3% | 7.1% |
| Other income | 8 | 8 | 16 | 11 | 6 | 5 | 6 | 9 |
| Net profit | 38 | 31 | 58 | 56 | 54 | 33 | 45 | 38 |
| EPS (₹) | 15.37 | 12.34 | 23.30 | 22.33 | 21.69 | 13.04 | 17.95 | 15.17 |
| Revenue YoY | +37.0% | +38.9% | +20.4% | +29.7% | ||||
| Profit YoY | +41.1% | +5.6% | -23.0% | -32.1% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 806 | 1,003 | 1,296 | 1,716 | 2,276 | 2,432 |
| EBITDA | 86 | 125 | 201 | 157 | 257 | 225 |
| Net profit | 62 | 99 | 162 | 116 | 188 | 170 |
| EPS (₹) | 24.64 | 39.72 | 64.60 | 46.30 | 75.01 | 67.85 |
| Revenue growth | +24.5% | +29.2% | +32.5% | +32.6% | +31.1% | |
| Profit growth | +61.2% | +62.7% | -28.3% | +62.0% | -7.5% | |
| Dividend / share (₹) | 2.00 | 8.00 | 16.00 | 24.00 | 32.00 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +31.4% | +22.8% | +31.1% |
| Net profit | +23.6% | +15.0% | -7.5% |
| EPS | +23.6% | +15.0% | – |
| Share price | – | -9.3% (2y) | -34.7% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 589 | 712 | 770 | 873 |
| Borrowings | – | 0 | 0 | 0 | 0 |
| Cash & equivalents | – | 500 | 506 | 537 | 449 |
| Total assets | – | 985 | 1,078 | 1,518 | 1,989 |
| Fixed assets | – | 69 | 60 | 64 | 117 |
| Capital work in progress | – | 1 | 0 | 0 | 0 |
| Investments | – | 0 | 53 | 0 | 0 |
| Receivables | – | 108 | 153 | 185 | 214 |
| Inventory | – | 190 | 228 | 548 | 1,027 |
| Payables | – | 228 | 198 | 456 | 783 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 101 | 58 | 93 | 65 | -15 |
| Cash from investing | 5 | 18 | 22 | 31 | 19 |
| Cash from financing | -9 | -24 | -44 | -66 | -92 |
| Capex | 10 | 9 | 11 | 2 | 4 |
| Free cash flow | 91 | 50 | 82 | 64 | -19 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 16.9% | 22.7% | 15.0% | 21.5% |
| ROCE % | – | 22.9% | 31.0% | 20.5% | 29.4% |
| Debtor days | – | 39 | 43 | 39 | 34 |
| Inventory days | – | 193 | 140 | 208 | 272 |
| Payable days | – | 231 | 122 | 173 | 207 |
| Cash conversion cycle (days) | – | 1 | 61 | 74 | 99 |
| Working capital days | – | 183 | 162 | 136 | 120 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 75.00% |
| FIIs | 2.64% |
| DIIs | 7.09% |
| of which Mutual funds | 7.01% |
| Public (non-institutions) | 15.27% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| Promoter group | % |
|---|---|
| AstraZeneca Pharmaceuticals AB | 75.00% |
| Public holders above 1% | % |
|---|---|
| Nippon Life India Trustee Ltd-a/c Nippon India Small CAP Fund(various Schemes) | 2.90% |
| Tejas Bhalchandra Trivedi | 2.30% |
| ICICI Prudential - Various Schemes | 2.18% |
| Shivani T. Trivedi | 1.72% |
| Bandhan - Various Schemes | 1.50% |
| Prashant Jain | 1.10% |
30,408 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| ASTRAZEN | ₹15,129 cr | 89.2x | 17.3x | 20.6% | 26.8% | 9.2% | +31.4% | 0.52% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-07-31 | Dividend | Dividend - Rs 36 Per Share |
| 2025-07-18 | Dividend | Dividend - Rs 32 Per Share |
| 2024-07-05 | Dividend | Dividend - Rs 24 Per Share |
| 2023-07-14 | Dividend | Dividend - Rs 16 Per Share |
| 2022-07-07 | Dividend | Dividend - Rs 8 Per Share |
| 2021-08-18 | Dividend | Interim Dividend - Rs 2 Per Share |
| 2020-08-20 | Dividend | Interim Dividend - Rs 2 Per Share |
| 2019-08-20 | Dividend | Interim Dividend - Re 1 Per Share |
| 2018-08-30 | Other | Annual General Meeting |
| 2017-09-04 | Other | Annual General Meeting |
| 2016-08-02 | Other | Annual General Meeting |
| 2015-08-20 | Other | Annual General Meeting |
| 2014-09-18 | Other | Annual General Meeting |
| 2013-08-07 | Other | Annual General Meeting |
| 2011-07-07 | Dividend | Dividend-Rs.10/- Per Share |
| 2010-05-06 | Dividend | Dividend-Rs.10/- Pr Share |
| 2009-04-29 | Other | Agm/Div-Rs.15/- Per Share |
| 2008-04-11 | Other | Agm/Div-Rs15 Per Share |
| 2008-01-04 | Bonus | Sch Of Agmt- Bonus Deb1:1 |
| 2007-04-25 | Other | Agm Bc Start Date/Purpose Revised |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Pharmaceuticals: Marketing and trading of pharmaceutical product
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | ASTRAZEN |
| BSE code | 506820 |
| ISIN | INE203A01020 |
| Face value | ₹2.0 |
| Incorporated | 1979-07-11 |
| Website | www.astrazeneca.com/india |
| Plants (India / abroad) | 1 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.